Affimed N.V. AFMDQ
0.01 USD 0.00 (+66.67%)
At closeNov 3, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.00001 52-week range 0.05
- YTD
- +4,900.00%
- 1 year
- +4,900.00%
- Market cap
- 81.96K
- EPS (ttm)
- -124.44
- YTD return
- +4900.00%
- 1-year return
- +4900.00%
- Volume
- 2.60K
- Avg volume
- 12.39K
- Open
- 0.0001
- Previous close
- 0.003
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.00001 – 0.05
2Y -3.2650 (-99.85%)
Financials — quick view
AFMDQ Revenue — quarterly 155.00K
AFMDQ Net income — quarterly -15.14M
AFMDQ EPS — quarterly -0.94
News
Affimed Announces Receipt of Nasdaq Delisting Notice 
Affimed Announces Filing for the Opening of Insolvency Proceedings 
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting 
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting 
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting 
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement 
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting 
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) 
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Your note
Sign in to keep a note on AFMDQ — it syncs with the Stock Master app.